Business context and reporting period
This unaudited Form 10-Q covers the quarter and nine months ended September 30, 2015. The filing is by ZIOPHARM Oncology, Inc. (the company identified in the supplied filing), not Alaunos Therapeutics, Inc. ZIOPHARM was a clinical-stage biopharmaceutical company focused on cancer therapies and graft-versus-host disease (GvHD); it reported minimal collaboration revenue and no approved products.
Key financial metrics
| Metric | Three months ended Sept. 30, 2015 | Nine months ended Sept. 30, 2015 | Comparable 2014 period |
|---|---|---|---|
| Revenue | $1.9 million | $2.4 million | $0.6 million quarter; $1.0 million nine months |
| Research and development expense | $17.0 million | $98.6 million | $9.7 million quarter; $24.6 million nine months |
| General and administrative expense | $3.1 million | $14.4 million | $2.8 million quarter; $9.3 million nine months |
| Net loss | $18.2 million | $110.6 million | $6.1 million quarter; $21.4 million nine months |
| Net loss per share | $0.14 | $0.89 | $0.06 quarter; $0.21 nine months |
| Cash and cash equivalents | $163.8 million at Sept. 30 | $42.8 million at Dec. 31, 2014 | |
| Operating cash flow | $23.8 million provided | $26.8 million used in first nine months of 2014 |
There was no meaningful product gross margin reported; revenue was collaboration and license-related, while the company remained loss-making. Cash equivalents included $160.9 million in a U.S. Treasury money-market fund. Current assets were $172.5 million, current liabilities $29.6 million, and working capital $142.9 million. Total liabilities were $79.5 million, including $56.4 million of deferred revenue; the filing does not report interest-bearing debt.
Material changes and unusual items
- Nine-month R&D expense rose by $74.0 million year over year, chiefly due to a $67.3 million noncash charge for shares issued for the MD Anderson license and a $10.0 million GvHD technology-access charge. Higher CAR-T spending was partly offset by reduced discovery, nonclinical, and small-molecule program costs.
- Revenue increased as the company recognized $1.6 million under the Ares Trading (Merck KGaA subsidiary) collaboration. The company received $57.5 million of the $115.0 million upfront payment made to Intrexon; its share was recorded as deferred revenue and recognized over the estimated service period. Deferred revenue at quarter-end included $55.9 million from this agreement.
- Cash increased by $121.0 million during the first nine months, principally from $94.3 million net proceeds from a February public offering and the Ares Trading receipt. Operating cash flow was positive largely in the context of the upfront collaboration payment and increased deferred revenue; it should not be read as recurring operating profitability.
- Common shares outstanding increased from 104.5 million at year-end 2014 to 130.9 million at September 30, 2015, reflecting the public offering and 11.7 million shares issued for the MD Anderson license. The company also reported 2.2 million option exercises in the equity statement; the stock-option note reports 2.9 million exercised, a difference investors should check.
Outlook, commentary, and risks
Management estimated that available cash would fund operations into the first quarter of 2018, based on current plans. It warned that clinical-development costs, program changes, regulatory developments, and financing conditions could shorten that runway; it had no committed additional capital and expected to need future financing. No assurance was given that additional funds would be available on acceptable terms.
- Planned milestones included early data from breast cancer and glioblastoma studies and interim CAR-T data in the fourth quarter of 2015; a further CAR-T clinical program was planned for 2015, with additional CAR-T, TCR, NK-cell, allogeneic-cell, and GvHD preclinical work planned for 2016. These were expectations, not guarantees.
- The company had completed Phase 2 monotherapy studies of Ad-RTS-IL-12 plus veledimex in melanoma and breast cancer, but planned to pause further intratumoral melanoma development amid a changing and competitive standard of care. Breast cancer and glioblastoma studies continued. The filing described early clinical findings but emphasized that candidates remained investigational.
- Key risks included clinical and regulatory failure, adverse events and complex cell-therapy manufacturing, intense competition, dependence on Intrexon and MD Anderson licenses and collaborators, intellectual-property disputes, possible dilution from future financing, and uncertain commercialization and reimbursement. The company also disclosed related-party arrangements with Intrexon; its director Randall Kirk was Intrexon’s CEO, director, and largest stockholder.
- The GvHD agreement required a $10 million access fee and reimbursement of R&D costs, with equal sharing of product profits; the access-fee liability was paid in October 2015. MD Anderson research funding was specified at $15 million to $20 million annually for three years. Contractual obligations totaled $41.6 million, including $39.4 million in royalty and license fees.
- The filing reported no material legal proceedings and stated that disclosure controls were effective, with no material change in internal control over financial reporting during the quarter.
Important facts for investors to verify
- Confirm the issuer and period: this source is ZIOPHARM Oncology’s 2015 third-quarter 10-Q, despite the request metadata naming Alaunos Therapeutics.
- Reconcile reported option exercises (2.2 million in the equity statement versus 2.9 million in the option-activity note) and the share count: the balance sheet reports 130,887,901 shares at September 30, while the cover reports 130,888,901 shares at October 26.
- Assess the cash-runway estimate against planned clinical spending, MD Anderson funding, the GvHD agreement, and the absence of committed future financing.
- Review recognition and duration assumptions for the $57.5 million Ares Trading upfront share, related deferred revenue, and any future milestone or royalty proceeds.
- Evaluate the clinical evidence and timing underlying management’s stated 2015–2016 milestones, together with licensing, manufacturing, safety, and competitive risks.